https://www.businessline.global/galderma-announces-top-line-results-from-phase-2-clinical-dose-escalating-study-with-azzalure-dysport-abobotulinumtoxina/press-release/
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)